On 20 March 2024, the respiratory syncytial virus (RSV) vaccine Abrysvo was registered by the Therapeutic Goods Administration (TGA). Abrysvo is indicated for:

  • pregnant people between 24 and 36 weeks gestation for the prevention of lower respiratory tract disease caused by RSV in infants from birth to 6 months of age 
  • adults aged 60 years and older for the prevention of lower repiratory tract disease caused by RSV.

Abrysvo is a recombinant respiratory syncytial virus pre-fusion F protein vaccine. Guidance on its use is yet to come.

TGA: Guidance and resources on Abrysvo